Efficacy observation of deep hyperthermia combined with recombinant human vascular endothelial inhibitor injection and AP regimen in treatment of advanced non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the efficacy of deep hyperthermia combined with recombinant human vascular endothelial inhibitor injection and AP (pemetrexed + cisplatin) regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its effects on serum tumor marker levels and immune function of patients.Methods:In this prospective randomized controlled study, 106 patients with advanced NSCLC who were admitted to the Seventh People's Hospital of Hebei Province from January 2016 to January 2022 were included, and were divided into two groups according to the random number table method, with 53 cases in each group. The control group was treated with recombinant human vascular endothelial inhibitor injection combined with AP regimen. The observation group was given recombinant human vascular endothelial inhibitor injection combined with AP regimen and deep hyperthermia. After 4 consecutive cycles of treatment, the short-term efficacy of the two groups was observed. Chemiluminescence assay was used to detect the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and cytokeratin fragment 19 CYFR21-1 before and after treatment. T lymphocyte subsets in peripheral blood were detected by flow cytometry. The occurrence of adverse reactions was compared between the two groups.Results:The objective response rates in observation group and control group were 58.49% (31/53) and 37.74% (20/53), the disease control rates in observation group and control group were 92.45% (49/53) and 75.47% (40/53), the observation group was higher than the control group ( χ2 = 4.53, P = 0.033; χ2 = 5.62, P = 0.018). The differences in serum carcinoembryonic antigen (CEA), glycoantigen 125 (CA125) and CYFR21-1 levels between the two groups before treatment were not statistically significant (all P > 0.05), they were lower in both groups after treatment than before treatment (all P < 0.05), and they were lower in the observation group after treatment than in the control group after treatment (all P < 0.05). The differences in peripheral blood CD3 +, CD4 + and CD8 + T-cell levels and CD4 + to CD8 + T-cell ratio (CD4 +/CD8 +) between the two groups before treatment and in the observation group before and after treatment were not statistically significant (all P > 0.05). Peripheral blood CD3 + and CD4 + T-cell levels and CD4 +/CD8 + in the control group after treatment were lower than before treatment (all P < 0.05), and the peripheral blood CD8 + T-cell level was higher than before treatment ( P < 0.05). CD3 + and CD4 + cell levels and CD4 +/CD8 + in the observation group after treatment were higher than those in the control group after treatment, CD8 + T-cell level was lower than the control group after treatment, and the differences were statistically significant (all P < 0.001). There were different degree of gastrointestinal reactions, bone marrow suppression, liver and kidney damage and cardiotoxicity in both groups during treatment, but the differences in the incidence of each adverse reaction between the two groups were not statistically significant (all P > 0.05). Conclusions:Deep hyperthermia combined with recombinant human vascular endothelial inhibitor injection and AP regimen in the treatment of advanced NSCLC can effectively reduce the serum tumor marker levels, improve the immunosuppression status of the body and enhance the recent efficacy, and the overall adverse reactions are controllable and well tolerated by patients.